Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Cheryl Kefauver"'
Autor:
Peter Zang, Tanya Dorff, Zhang-Xu Liu, Denice Tsao-Wei, Susan Groshen, Cheryl Kefauver, Czarina Patricio, Anishka D'Souza, Sarah Chevalier, Sumanta Pal, Diane DaSilva, Martin Kast, David Quinn
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a75df81cfb75aecbe264bba9201229c3
https://doi.org/10.1136/jitc-2022-sitc2022.0561
https://doi.org/10.1136/jitc-2022-sitc2022.0561
Autor:
Sarmad Sadeghi, Laurence A. Doyle, Edward M. Newman, Primo N. Lara, Rahul R. Parikh, Christopher J. Hoimes, David I. Quinn, Susan Groshen, Denice D. Tsao-Wei, Tanya B. Dorff, Amir Mortazavi, Cheryl Kefauver
Publikováno v:
Journal of Clinical Oncology. 37:2682-2688
PURPOSE Patients with metastatic urothelial carcinoma are often ineligible for cisplatin-based treatments. A National Cancer Institute Cancer Therapy Evaluation Program–sponsored trial assessed the tolerability and efficacy of a gemcitabine-eribuli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bfd60ad7ccb67d6ca3a5177bb1df30f
https://doi.org/10.1200/jco.19.00861
https://doi.org/10.1200/jco.19.00861
Autor:
Sarmad Sadeghi, Rahul Atul Parikh, Denice D. Tsao-Wei, Susan G. Groshen, Ming Li, Leonard Joseph Appleman, Scott T. Tagawa, David M. Nanus, Ana M. Molina, Cheryl Kefauver, Moshe Chaim Ornstein, Brian I. Rini, Robert Dreicer, David I. Quinn, Primo \\'Lucky\\' N. Lara
Publikováno v:
Journal of Clinical Oncology. 40:4529-4529
4529 Background: Immune checkpoint blockade has revolutionized mRCC Tx, but primary and acquired resistance continues to result in poor patient outcomes. OX40 (CD-134) mediates IO resistance. Co-stimulatory OX40 (CD-134) activates exhausted T-cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d937584ae5836043b2b328807de2eaa7
https://doi.org/10.1200/jco.2022.40.16_suppl.4529
https://doi.org/10.1200/jco.2022.40.16_suppl.4529
Autor:
William Blum, Mitch A. Phelps, Rebecca B. Klisovic, Darlene M. Rozewski, Wenjun Ni, Katie A. Albanese, Brad Rovin, Cheryl Kefauver, Steven M. Devine, David M. Lucas, Amy Johnson, Larry J. Schaaf, John C. Byrd, Guido Marcucci, Michael R. Grever
Publikováno v:
Haematologica, Vol 95, Iss 7 (2010)
Background A pharmacokinetically derived schedule of flavopiridol administered as a 30 min intravenous bolus followed by 4-hour continuous intravenous infusion (IVB/CIVI) is active in fludarabine-refractory chronic lymphocytic leukemia, but no studie
Externí odkaz:
https://doaj.org/article/0067fbbaef9b4bf9a6db24460b917eb7
Autor:
Steven M. Devine, Zhiliang Xie, Zhongfa Liu, William Blum, Cheryl Kefauver, Michael R. Grever, Kenneth K. Chan, Lenguyen Huynh, Rebecca B. Klisovic, James A. Zwiebel, Guido Marcucci, John C. Byrd
Publikováno v:
Leukemia & Lymphoma. 55:1332-1336
We hypothesized that GTI-2040, a 20-mer oligonucleotide complementary to the R2 subunit mRNA of ribonucleotide reductase, combined with high dose cytarabine (HiDAC) would result in enhanced cytotoxicity by favoring Ara-CTP DNA incorporation. In a pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2540a680cd8a820cdaa82291ed3a6a9
https://doi.org/10.3109/10428194.2013.838764
https://doi.org/10.3109/10428194.2013.838764
Autor:
Alison Walker, John Curfman, Ann-Kathrin Eisfeld, Samson T. Jacob, Ramasamy Santhanam, Cheryl Kefauver, Susan Geyer, Kenneth K. Chan, Sebastian Schwind, Hongyan Wang, Guido Marcucci, Susan P. Whitman, William Blum, Michael A. Caligiuri, Ramiro Garzon, Celia Garr, Clara D. Bloomfield, Steven M. Devine, Michael R. Grever, Somayeh S. Tarighat, Danilo Perrotti, John C. Byrd, Rebecca B. Klisovic
Publikováno v:
Blood. 119:6025-6031
We recently reported promising clinical activity for a 10-day regimen of decitabine in older AML patients; high miR-29b expression associated with clinical response. Subsequent preclinical studies with bortezomib in AML cells have shown drug-induced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d74310a3df3bcd1880cf99430a4e4e6e
https://doi.org/10.1182/blood-2012-03-413898
https://doi.org/10.1182/blood-2012-03-413898
Autor:
William E. Carson, Cheryl Kefauver, Lai Wei, Kari Kendra, Cynthia Taylor, Valerie P. Grignol, Helen X. Chen, Amanda Kibler, Kiran V. Relekar, Thomas Olencki, Michael Walker
Publikováno v:
Journal of Immunotherapy. 34:509-515
Bevacizumab is a humanized recombinant monoclonal antibody that neutralizes vascular endothelial growth factor, an agent with proangiogenic effects in melanoma. Interferon alpha (IFN-α) has antiangiogenic properties through its ability to downregula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f167d8e153ad7366a91b4e25d27d5cb
https://doi.org/10.1097/cji.0b013e31821dcefd
https://doi.org/10.1097/cji.0b013e31821dcefd
Autor:
John Curfman, Heiko Becker, Alison Walker, William Blum, Shujun Liu, Cheryl Kefauver, Larry J. Schaaf, Ramiro Garzon, Jon Mickle, Susan P. Whitman, John C. Byrd, Rebecca B. Klisovic, Jason C. Chandler, Steven M. Devine, Guido Marcucci, Mitch A. Phelps, Xiaoxia Yang, Michael R. Grever, Darlene M. Rozewski
Publikováno v:
Journal of Clinical Oncology. 28:4919-4925
Purpose Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia. Patients and Methods Thirty-one adult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f13d3341e7e60773f2a4de8a70ac1b55
https://doi.org/10.1200/jco.2010.30.3339
https://doi.org/10.1200/jco.2010.30.3339
Autor:
Jacqueline E. Payton, Camille N. Abboud, Todd A. Fehniger, William Blum, Ravi Vij, Guido Marcucci, Cheryl Kefauver, John C. Byrd
Publikováno v:
Blood. 113:1002-1005
Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0749ad68288ba81f86f3608914e1544c
https://doi.org/10.1182/blood-2008-04-152678
https://doi.org/10.1182/blood-2008-04-152678
Autor:
Guido Marcucci, Lenguyen Huynh, Zhiliang Xie, Jiuxia Pang, Rebecca B. Klisovic, John C. Byrd, Cheryl Kefauver, William Blum, Shujun Liu, Zhongfa Liu, Tamara Vukosavljevic, Michael R. Grever, James A. Zwiebel, Kenneth Chan, Steven M. Devine, Xiaohui Wei
Publikováno v:
Clinical Cancer Research. 14:3889-3895
Purpose: Inhibition of ribonucleotide reductase reduces the availability of the endogenous pool of deoxycytidine and may increase cytarabine (AraC) cytotoxicity. We performed a phase I dose escalation trial of AraC combined with GTI-2040, a 20-mer an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90acdf106a03b931c3688c950787074c
https://doi.org/10.1158/1078-0432.ccr-08-0109
https://doi.org/10.1158/1078-0432.ccr-08-0109